Geneviève Garon

Also affiliated with Sanofi (Canada), University of Colorado Denver

MedicineEconomics, Econometrics and FinanceBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial”.

Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial

Journal of the American Heart Association(2023)10.1161/jaha.122.029216

N/A

1.1DataRank · unranked

40 citations

Philippe Gabríel Steg, Yann Poulouin, Deepak L. Bhatt, Vera Bittner, Rafael Díaz +10 more

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

European Heart Journal - Cardiovascular Pharmacotherapy(2024)10.1093/ehjcvp/pvae025

N/A

0.483DataRank · unranked

24 citations

Philippe Gabríel Steg, Michael Szarek, Deepak L. Bhatt, Vera Bittner, Rafael Díaz +82 more

Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial

Diabetes Care(2025)10.2337/dc24-2110

N/A

0.360DataRank · unranked

10 citations

Michael Szarek, J. Wouter Jukema, Christa M. Cobbaert, Esther Reijnders, Vera Bittner +9 more